Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil

Next Previous
Trial Profile

A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phenylephrine/tropicamide (Primary) ; Phenylephrine; Tropicamide
  • Indications Mydriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms MIST-1
  • Sponsors Eyenovia

    • Most Recent Events

    • 13 Nov 2019 According to an Eyenovia media release, results from Phase III MIST-1 and MIST-2 studies were presented at the American Academy of Optometrys 3rd World Congress of Optometry (AAOPT)
    • 02 Oct 2019 According to an Eyenovia media release, results from Phase III MIST-1 and MIST-2 studies will be presented at the American Academy of Optometrys 3rd World Congress of Optometry (AAOPT) on 25th Oct 2019 (Orlando, FL) by Tom Walters (Md, Keystone Research, Ltd).
    • 30 Jan 2019 According to an Eyenovia media release, the company expects to present the detailed results from the trial in a forthcoming scientific forum.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top